Vical

News

Vical slashes staff after culling phase II antifungal

US biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, its last remaining clinical-stage asset.

News

InnoCare and Eli Lilly logos over a handshake graphic in the background

Lilly forges $3.35bn alliance with China's InnoCare

Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks